1,080 results on '"Wahlestedt, Claes"'
Search Results
2. Microglia contribute to methamphetamine reinforcement and reflect persistent transcriptional and morphological adaptations to the drug
3. Author Correction: Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis
4. Investigating the Synergistic Potential of Low-Dose HDAC3 Inhibition and Radiotherapy in Alzheimer’s Disease Models
5. Amplifying gene expression with RNA-targeted therapeutics
6. Correction: Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL TM)
7. Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL TM)
8. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT
9. The Machine that Builds Itself: How the Strengths of Lisp Family Languages Facilitate Building Complex and Flexible Bioinformatic Models
10. Zipf's law emerges asymptotically during phase transitions in communicative systems
11. A novel knockout mouse model of the noncoding antisense Brain-Derived Neurotrophic Factor (Bdnf) gene displays increased endogenous Bdnf protein and improved memory function following exercise
12. Direct Administration and Gene Modulation Using Antisense Oligonucleotides Within the CNS
13. Generation and Characterization of a Novel Prkcd-Cre Rat Model.
14. The interaction of radiotherapy and dual inhibition of BET and HAT/p300 in colorectal cancer.
15. Contextualizing the Role of Osteopontin in the Inflammatory Responses of Alzheimer’s Disease
16. Selective RNA‐targeting of mTORC1 and 2 to ameliorate Alzheimer’s Disease pathogenesis
17. A new strategy for Alzheimer’s disease: low‐dose combination of radiotherapy and pharmacological epigenetic perturbation
18. Chapter 3 - Epigenomics of neurological disorders
19. Alcohol use disorder causes global changes in splicing in the human brain
20. Microglia contribute to methamphetamine reinforcement and reflect persistent transcriptional and morphological adaptations to the drug
21. Inhibition of HDAC3 reverses Alzheimer’s disease-related pathologies in vitro and in the 3xTg-AD mouse model
22. List of contributors
23. Epigenomics of neurological disorders
24. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies
25. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study
26. A Universal Plasmid Library Encoding All Permutations of Small Interfering RNA
27. M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer’s disease genes and improving memory
28. Low-Dose Chidamide Treatment Displays Sex-Specific Differences in the 3xTg-AD Mouse
29. Nucleic acid-based therapeutics for the treatment of central nervous system disorders
30. Long non-coding RNA-targeting therapeutics: discovery and development update
31. Dysregulation of the Histone Demethylase KDM6B in Alcohol Dependence is Associated with Epigenetic Regulation of Inflammatory Signaling Pathways
32. NotI Subtraction and NotI-Specific Microarrays to Detect Copy Number and Methylation Changes in Whole Genomes
33. Embryonic Stem Cells Develop into Functional Dopaminergic Neurons after Transplantation in a Parkinson Rat Model
34. Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD
35. Leptin Induces Vascular Permeability and Synergistically Stimulates Angiogenesis with FGF-2 and VEGF
36. Novel approach reveals genomic landscapes of single-strand DNA breaks with nucleotide resolution in human cells
37. Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis
38. Potent and Nontoxic Antisense Oligonucleotides Containing Locked Nucleic Acids
39. Supplementary Table 1 from Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma
40. Data from Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma
41. Supplementary Material -Table Legends, Figures and Legends 1-3 from Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma
42. Supplementary Table 2 from Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma
43. Data from Vitamin C Sensitizes Melanoma to BET Inhibitors
44. Supplementary Figure from DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
45. Supplemental info from Vitamin C Sensitizes Melanoma to BET Inhibitors
46. Supplementary Data from DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
47. Supplementary Table from Kinetics of Senescence-associated Changes of Gene Expression in an Epithelial, Temperature-sensitive SV40 Large T Antigen Model
48. The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer
49. Transcriptomics for Clinical and Experimental Biology Research: Hang on a Seq
50. Drug and disease signature integration identifies synergistic combinations in glioblastoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.